CD4 and breast carcinoma: In breast cancer, TSLP produced by cancer cells activates DC and results in Th2 inflammation, which promotes tumorigenesis [20]; whereas in mouse, TSLP can induce immunosuppressive factors by activating CD4+ T cells that promote Th2-mediated immune responses [21].